NCT06875986Recruiting
REXULTI General Use Results Survey in Patients With Hyperactivity, or Aggressive Behavior Associated With Alzheimer's Dementia
REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 12 Mar 2025
- Start date
- 17 Apr 2025
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Diseases
- Alzheimer disease
- NCT number
- NCT06875986
What you commit to
- Study type: Observational
- Planned participants: 200
- From 17 Apr 2025 to the primary completion date, 30 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- Patients diagnosed with Alzheimer's disease
Age in the registry: 15 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmacovigilance Department Coordinator of this site? Confirm its status | Osaka | Japan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.